摘要
磷脂酶a2(PLA2s)的酶,它裂开磷脂专门在sn-2位置解放自由脂肪酸,主要是花生四烯酸(AA)和溶血磷脂(lpl)。抑制PLA2防止AA和lpl的解放。因此,研究人员一直在考虑PLA2s可能是一个更好的比下游cyclooxygense酶和脂氧合酶的治疗目标。几个亚型的PLA2s存在,主要分为分泌PLA2s(sPLA2),胞质PLA2s(cPLA2)和钙独立PLA2s(iPLA2)、血小板激活因子-酰基水解酶(PAF-AH),溶酶体PLA2(LPLA2)adipose-specific PLA2(Ad - PLA)。每个同种型PLA2s不同的化学结构和生理功能。sPLA2s(团体活动花絮,V和X)描述为酶促炎调停,但他们的角色在癌症是有争议的。组IVA IVB和印度河流域文明司长委任cPLA2s存在于人类只有组IVA cPLA2在各种癌症和炎症的病理生理学中扮演关键角色。iPLA2在炎症和癌症的作用是有限的。脂蛋白相关PLA2(集团VIIA PLA2)PAF-AH同种型,在动脉粥样硬化的关键作用。数个同种型PLA2抑制剂已经被发达国家和一些特定的PLA2s抑制剂目前正在临床试验对各种炎症和肿瘤疾病。本文关注的是最近的实验证据支持这一概念,PLA2s是因果与癌症和炎症相关疾病的病理学和讨论具体同种型PLA2抑制剂的潜在效用作为预防和/或治疗药物。
关键词: 磷脂酶A2、炎症、癌症、PLA2同种型特定抑制剂。
Current Drug Targets
Title:Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Volume: 17 Issue: 16
Author(s): Nagendra Sastry Yarla, Anupam Bishayee, Lakshmipathi Vadlakonda, Ramakrishna Chintala, Govinda Rao Duddukuri, Pallu Reddanna and Kaladhar S.V.G.K. Dowluru
Affiliation:
关键词: 磷脂酶A2、炎症、癌症、PLA2同种型特定抑制剂。
摘要: Phospholipase A2s (PLA2s) are group of enzymes, which cleave phospholipids specifically at sn-2 position to liberate free fatty acid, mostly arachidonic acid (AA) and lysophospholipids (LPLs). Inhibition of PLA2 prevents the liberation of AA and LPLs. Hence, researchers have been considering PLA2s could be a better therapeutic target than the downstream enzymes cyclooxygense and lipoxygenase. Several isoforms of PLA2s exist; they are mainly divided into secretory PLA2s (sPLA2), cytosolic PLA2s (cPLA2), and calcium independent PLA2s (iPLA2), platelet activating factor- acyl hydrolase (PAF-AH), lysosomal PLA2 (LPLA2), adipose-specific PLA2 (Ad- PLA). Each isoform of PLA2s is different in its chemical structure and physiological functions. sPLA2s (Groups IIA, V and X) are well characterized as proinflammatory mediating enzymes but their role in cancer is controversial. Groups IVA, IVB and IVC cPLA2s are present in humans but only Group IVA cPLA2 plays key role in pathophysiology of various cancers and inflammation. The role of iPLA2 in inflammation and cancer is limited. Lipoprotein associated PLA2 (Group VIIA PLA2), a PAF-AH isoform, has key role in atherosclerosis. Several isoform specific PLA2 inhibitors have been developed and some of the PLA2s inhibitors are currently under clinical trials for various inflammatory and oncologic diseases. This review focuses on the recent experimental evidences to support the notion that PLA2s are causally implicated in the pathobiology of cancer and inflammatory related disorders and discuss the potential utility of isoform specific PLA2 inhibitors as preventive and/or therapeutic agents.
Export Options
About this article
Cite this article as:
Nagendra Sastry Yarla, Anupam Bishayee, Lakshmipathi Vadlakonda, Ramakrishna Chintala, Govinda Rao Duddukuri, Pallu Reddanna and Kaladhar S.V.G.K. Dowluru , Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases, Current Drug Targets 2016; 17 (16) . https://dx.doi.org/10.2174/1389450116666150727122501
DOI https://dx.doi.org/10.2174/1389450116666150727122501 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Induction of Quinone Reductase NQO1 by Resveratrol in Human K562 Cells Involves the Antioxidant Response Element ARE and is Accompanied by Nuclear Translocation of Transcription Factor Nrf2
Medicinal Chemistry Molecular Pathways Involved in Apoptotic Cell Death in the Injured Cochlea: Cues to Novel Therapeutic Strategies
Current Pharmaceutical Design A Chemical Genetics Approach for Specific Differentiation of Stem Cells to Somatic Cells: A New Promising Therapeutical Approach
Combinatorial Chemistry & High Throughput Screening Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Physiologic Tailoring of Treatment in Resistant Hypertension
Current Cardiology Reviews The Manzamines as an Example of the Unique Structural Classes Available for the Discovery and Optimization of Infectious Disease Controls Based on Marine Natural Products
Current Pharmaceutical Design Sleep in Pediatric Pulmonary Diseases
Current Respiratory Medicine Reviews Ca2+-Dependent Signaling Pathways in the Heart: Potential Drug Targets for Cardiac Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Effect of Methylxanthine Derivatives on Doxorubicin Transport and Antitumor Activity
Current Drug Metabolism Resveratrol: A Therapeutic Approach to Neurodegenerative Diseases and Aging
Mini-Reviews in Organic Chemistry C-Reactive Protein and Atherosclerosis: An Update
Vascular Disease Prevention (Discontinued) Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
Current Pharmaceutical Design Homocysteine and Heart Failure: An Overview
Recent Patents on Cardiovascular Drug Discovery Vascular Endothelin and Hypertension - From Receptors to Medicine
Current Hypertension Reviews Hyperuricemia: Is it a Risk Factor for Vascular Endothelial Dysfunction and Associated Cardiovascular Disorders?
Current Hypertension Reviews Protein Kinase C Isoforms - Implications to Thrombosis
Current Signal Transduction Therapy Dapsone, More than an Effective Neuro and Cytoprotective Drug
Current Neuropharmacology Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
Current Vascular Pharmacology